

**Protocol Title**: A phase IIIb, open-label, multicentre, international randomised controlled trial of simplified treatment monitoring for 8 weeks glecaprevir (300mg)/pibrentasvir (120mg) in chronic HCV treatment naïve patients without cirrhosis

Protocol No: VHCRP1701

## **Protocol Exemption Request Form**

To be completed by the site			
Site Information			
Site Name:			
Principal Investigator:			
Site Fax Number		Email:	
Subject Information			
Subject Initials (e.g. FF-LL)		Date of Birth (dd/mm/yyyy)	
Participant Study ID: (if already enrolled)	1701		
Exemption Request (tick one only)	Eligibility criteria	☐ During study	conduct
Requested By (name):		Request Date: (dd/mm/yyyy)	
Description of exemption request: (include specific criteria and reason why exemption is needed)			
Fax to +61 2 9385 9214 or email to smartc@kirby.unsw.edu.au			
To be completed by the Kirby Institute			
Name of Investigator:		Granted	□ Yes □ No
Signature of Investigator	r	Date: (dd/mm/yyyy)	
Protocol Exemption Nun	nber:	Faxed to site: (dd/mm/yyyy)	

If an exemption is granted for study eligibility criteria, please enter the protocol exemption number in the screening e-CRF.

Please keep this form in the Study Investigator Folder